Develops precision medicines for genetically defined muscle diseases including Duchenne muscular dystrophy and cardiomyopathies.
Develops precision medicines for genetically defined muscle diseases including Duchenne muscular dystrophy and cardiomyopathies.
Has no approved product and so no sales; trial spending is funded by raising money from investors and from cash on hand. Any future income depends on regulators approving one of its medicines, which would then be sold to a small group of specialist doctors.
Moat: none (IP / patents). Clinical-stage biotech with novel muscle-targeted mechanisms but no approved products yet.
Headquarters: Boulder, Colorado, US · Founded: 2017 · Employees: 146
Size Edgewise Therapeutics (EWTX) is a United States Health Care company (Biotechnology) with a market value of $4.53B, the 1249th largest of 3,085 United States companies the cockpit tracks. Shares closed at $41.37 on 18 Nov 2026.
Performance Over six months the shares gained 26.1%, against -0.3% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Valuation It trades at 2.77× book value against a peer median of 3.58× (10th cheapest of 21).
Price implies The share price implies a return on equity of about 14.2%; Edgewise Therapeutics delivers 92.1%, so the price asks less than the business earns today.
Short interest Short interest is 11.6% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$2.35M | -$2.27M | -$2.29M | -$1.73M | -$538,000 |
| EBITDA | -$216M | -$189M | -$157M | -$113M | -$71.1M |
| Net income | $1.01B | -$168M | -$134M | -$100M | -$67.6M |
| Free cash flow | -$202M | -$144M | -$110M | -$97.7M | -$58.2M |
| Capital expenditure | $382,000 | $256,000 | $1.31M | $5.75M | $5.55M |
| Total debt | $3.38M | $3.99M | $4.74M | $5.41M | $4.41M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics EWTX | $4.53B | +26% | n/a | 92% | 2.77× | 14.2% |
| Sarepta Therapeutics SRPT | $1.56B | -15% | -19% | -8% | 1.02× | 7.4% |
| Cytokinetics CYTK | $7.15B | -35% | +30% | n/a | n/a | n/a |
| BridgeBio Pharma BBIO | $15.2B | +14% | +167% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EWTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.1% | -5.3% | 7th highest of 21 |
| 6-month return | +26.1% | -0.3% | 5th highest of 21 |
| Return on equity | 92.2% | -18.6% | highest of 21 |
| Price / book | 2.77× | 3.58× | 10th cheapest of 21 |
| Trailing P/E | 5.0× | 30.6× | 2nd cheapest of 7 |
| ROE the price implies | 14.2% | 35.8% | 6th least demanding of 21 |
| ROE delivered | 92.1% | -18.6% | highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | 92% | 2.77× | 14.2% | 92.1% |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -2% | 1.32× | 13.5% | -1.9% |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 3% | 0.94× | 3.8% | 3.3% |
| Adaptive Biotechnologies ADPT | United States | $4.61B | +104% | +18% | -37% | 26.09× | 341.6% | -37.1% |
| Dianthus Therapeutics DNTH | United States | $4.73B | -5% | -12% | -23% | 3.81× | 39.0% | -22.6% |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $4.75B | 0% | +22% | -2% | 1.18× | 13.9% | -2.0% |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 37% | 1.04× | 9.8% | 36.7% |
| Cogent Biosciences COGT | United States | $4.84B | -16% | n/a | -100% | 10.72× | 44.4% | -99.6% |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -4% | 2.41× | 18.0% | -3.8% |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | -24% | 12.29× | 40.2% | -24.0% |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -26% | 2.36× | 30.5% | -25.6% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.28B | -1% | -28% | -64% | 2.32× | 24.5% | -63.8% |
| Anthem Biosciences ANTHEM.NS | India | $5.51B | +16% | -1% | 20% | 15.70× | 125.3% | 20.4% |
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | -36% | 3.78× | 34.6% | -36.5% |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | 13% | 1.31× | 16.7% | 13.3% |
| Caris Life Sciences CAI | United States | $5.59B | +24% | +61% | 17% | 8.74× | 51.8% | 17.2% |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -41% | 4.42× | 50.9% | -41.2% |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -15% | 3.38× | 37.0% | -14.6% |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | -41% | 4.98× | 37.2% | -41.3% |
| Scholar Rock SRRK | United States | $5.86B | -1% | n/a | -200% | 34.70× | 212.2% | -200.0% |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 6% | 1.95× | 7.4% | 6.0% |